Sonography of obstetric and gynecologic emergencies: Part I, Obstetric emergencies.
Explore the source record for details and available documents.
Emergencies↗
Biomedical subjects
H V Nghiem
Publications and source records attributed to H V Nghiem.
Sonography of obstetric and gynecologic emergencies: Part II, Gynecologic emergencies.
Explore the source record for details and available documents.
Adult↗
Prostate vascular flow: the effect of ejaculation as revealed on transrectal power Doppler sonography.
OBJECTIVE: The objective of our study was to determine the effect of ejaculation on prostate vascular flow. SUBJECTS AND METHODS: Using power Doppler technology, we performed four transrectal sonographic examinations before and immediately, 6 hr, and 24 hr after ejaculation in 10 healthy volunteers. Images were assessed by three independent observers. RESULTS: Ninety-seven percent of the images ranked as having the least flow were from the baseline examination. There was a significant difference between the rankings when categorized into the four time sets (mean score for the baseline group was 1.1, whereas for the immediate, 6-, and 24-hr postejaculation groups it was 2.5, 2.9, and 2.4, respectively (p<0.0001). The only statistically significant difference was between the baseline and the three remaining groups. Interobserver agreement was high, with the chance-corrected measure of agreement of 0.78. CONCLUSION: Transrectal sonography revealed that prostate vascular flow increases dramatically after ejaculation and remains elevated for at least 24 hr. This observation should be considered when power Doppler sonography is used to assess for potential hyperemia in patients suspected of having prostate abnormalities.
Adult↗
Prostate blood flow characteristics in the chronic prostatitis/pelvic pain syndrome.
PURPOSE: We determine whether the chronic prostatitis/pelvic pain syndrome is associated with abnormal prostate blood flow. MATERIALS AND METHODS: We used color Doppler ultrasonography to examine 53 patients with inflammation, 80 men without inflammation and 22 healthy controls. Images were recorded and scored using standardized criteria to characterize the degree and distribution of prostatic vascularity. RESULTS: Flow was observed to the entire prostatic capsule in 77% of patients but only 18% of controls (p<0.0001). Parenchymal flow was evaluated using several criteria. On a 2-point scale flow was classified as grade 2 in 74% of patients compared to 27% of controls (p<0.0001). Similar findings were noted on a Doppler spot scale, with flow classified as grade 2 in 47% of patients compared to 14% of controls (p<0.004). Patients also had more parenchymal Doppler spots than controls (p<0.01). Diffuse blood flow throughout the prostatic parenchyma was observed in 63% of patients compared to 36% of controls (p<0.03). There was no significant difference in the amount or distribution of blood flow in patients with and without inflammation. CONCLUSIONS: The chronic prostatitis/pelvic pain syndrome was associated with increased blood flow to the prostatic capsule and diffuse flow throughout the prostatic parenchyma. Despite technical limitations, color Doppler ultrasonography may provide objective documentation of prostate blood flow abnormalities in patients with this syndrome.
Adult↗
A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial.
The purpose of this study was to evaluate the safety and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in hepatic MRI of patients with suspected liver pathology. A Phase III, multicenter, randomized, double-blind, parallel group study was performed in adults with suspected liver pathology. All patients underwent contrast-enhanced computed tomography within 3 weeks prior to magnetic resonance scanning. Ninety-nine patients received OptiMARK, and 94 patients received Magnevist at a dose of 0.1 mmol/kg. Precontrast T1- and T2-weighted spin-echo imaging and T1-weighted gradient-echo imaging were performed, followed by T1-weighted gradient-echo imaging at 15-20 seconds, 1 minute, and 5 minutes after intravenous contrast injection. Three primary efficacy endpoints (confidence in lesion diagnosis, level of conspicuity, and lesion border delineation) were evaluated on the precontrast image set and compared with the pre plus postcontrast image set. Vital signs, physical examination, electrocardiograms (ECGs), and laboratory parameters (chemistry, hematology, and urinalysis) were measured at various time points. Adverse events were recorded. The study design and statistical analyses were chosen to demonstrate presumed equivalence of OptiMARK and Magnevist. There were no statistically significant differences in efficacy between OptiMARK and Magnevist as assessed by either blinded readers or the on-site principal investigators. No serious or unexpected adverse events were noted. Of the 193 patients receiving contrast media, 82 experienced a total of 154 adverse events. Thirty-three (21.4%) of these 154 adverse events were felt by the on-site investigators to be probably related to either study agent: 15 events in 9 patients in the OptiMARK group, and 18 events in 13 patients in the Magnevist group. Headache was the most common adverse event, occurring in 10.1% of the OptiMARK patients and 12.8% of the Magnevist patients. No clinically relevant trends were observed in any laboratory parameter or ECG findings in either treatment group. The results demonstrate the safety, efficacy, and equivalence of OptiMARK and Magnevist at a dose of 0.1 mmol/kg in hepatic magnetic resonance imaging of patients with suspected liver pathology.
Contrast Media↗
Treatment of inferior vena cava anastomotic stenoses with the Wallstent endoprosthesis after orthotopic liver transplantation.
PURPOSE: To evaluate the efficacy of the Wallstent endoprosthesis for treatment of stenotic or occlusive inferior vena cava (IVC) lesions refractory to balloon angioplasty in patients after orthotopic liver transplantation. MATERIALS AND METHODS: Wallstent endoprostheses were implanted in six patients with IVC anastomotic stenoses or occlusions that were refractory to balloon angioplasty. Follow-up included both duplex ultrasound (US) and clinical evaluations. RESULTS: Ten stents were successfully implanted in six patients. Five of six patients (83%) demonstrated primary patency on duplex US for a mean period of 11 months (range, 4-17 months). One patient's symptoms recurred within 3 weeks after intervention. This patient underwent repeated stent placement. Follow-up duplex US in this patient demonstrated primary assisted patency at 7 months. Mean clinical follow-up was 12 months (range, 7-18 months). Other than the previously described case, no patient developed recurrent symptoms of IVC stenosis or occlusion. Two patients who experienced hemorrhagic complications secondary to anticoagulation were treated successfully. CONCLUSIONS: The Wallstent endoprosthesis is a useful adjunct for treatment of IVC stenosis or occlusions in patients who have undergone orthotopic liver transplantation when these lesions are refractory to simple balloon angioplasty.
Adult↗
Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104).
We assessed a regimen of alternating regional and systemic therapy in patients with gastrointestinal malignancies with liver-dominant metastases for feasibility, toxicity, response rate, response duration, patterns of progression, and progression-free and overall survival. Regional therapy comprised selective hepatic transcatheter arterial chemoembolization (TACE) using a suspension of cisplatin and particulate polyvinyl alcohol. This procedure was delivered between cycles of protracted continuous infusion 5-fluorouracil (PCI-5FU) as systemic chemotherapy. Patient eligibility criteria included: (a) having histologically documented adenocarcinoma arising from a gastrointestinal primary site with unresectable liver metastases bidimensionally measurable on computerized tomography scan; (b) age greater than 18 years; and (c) performance status 0-2 (Zubrod). PCI-5FU (250 mg/m2/day) was administered i.v. for 28 days, followed by the first TACE (TACE 1) delivered to the hepatic artery supplying the lobe with the greatest tumor burden. Restaging was performed before TACE 2 and TACE 3, which followed at monthly intervals. PCI-5FU for 21 days was sandwiched between each of the TACE treatments. After the final TACE, maintenance PCI-5FU was given for 28 days of each 35-day cycle until toxicity or progression. Between December 23, 1991, and January 19, 1995, 32 patients were registered in this trial, of whom 27 were eligible; 20 completed one or more treatment cycles and were evaluable for radiographic response. Patients with colorectal liver metastases predominated (74%). Twelve (44%) of 27 patients had failed one or more prior treatment regimens. There were no treatment-related deaths, and hematological and hepatic toxicities were generally manageable and reversible. Two patients, however, developed hepatic abscesses requiring drainage, and one patient developed an infarcted gallbladder, which necessitated cholecystectomy. There were no patients with complete responses; there were 8 (40%) with partial responses, 4 (20%) with minor responses, 2 (10%) with stable disease, and 6 (30%) who progressed on the treatment. The median duration of response for partial responders was 4.2 months (127 days; range, 56-245 days). The median reduction in carcinoembryonic antigen for responders was 87.5%. Two patients underwent subsequent resection of residual metastases; one of them is still alive at 58.4 months follow-up. The predominant site of disease progression was the liver; 25% of the patients progressed in extrahepatic sites. The median overall survival for the whole group is 14.3 months (95% confidence interval, 7.2-16.2). Actuarial overall survival for the whole group at 1 year and 2 years is 57 and 19%, respectively. Alternating systemic PCI-5FU and regional TACE (cisplatin/polyvinyl alcohol) is an active and feasible regimen with manageable toxicities in patients with metastatic gastrointestinal malignancies with liver-dominant disease and merits further investigation. The complications seen were in line with those reported at other specialized centers.
Adenocarcinoma↗
Imaging of hepatic transplantation.
This article provides a clinical overview of liver transplantation. Preoperative radiologic imaging methods are discussed. Relevant surgical anatomy is illustrated, including vascular and biliary anastomoses. The radiologic features of vascular complications in liver transplantation are also reviewed.
Contraindications↗
CT angiography of the visceral vasculature.
CT angiography (CTA) is a minimally invasive technique that has proven to be clinically useful in evaluating the vasculature of the abdominal viscera. In many instances, the diagnostic information obtained from abdominal CTA is sufficient to avoid the expense and morbidity of conventional angiography. This article reviews the indications, technique, and pitfalls of abdominal CTA with specific emphasis on disorders of the hepatic, splenic, and superior mesenteric arteries and the portal venous system.
Angiography↗
Frontal lobe shortening in second-trimester fetuses with trisomy 21: usefulness as a US marker.
PURPOSE: To determine whether the frontal lobe is disproportionately smaller than normal in second-trimester fetuses with Down syndrome by using prenatal ultrasonographic (US) measurements of the frontothalamic distance (FTD). MATERIALS AND METHODS: The FTD, measured from the inner table of the frontal bone to the posterior margin of the thalamus, was measured in 43 fetuses (mean gestational age, 17.2 weeks +/- 1.3 [standard deviation]; range, 15.0-20.4 weeks) with chromosomally proved trisomy 21 and in 160 chromosomally normal fetuses (mean gestational age, 17.1 weeks +/- 1.5; range, 14.5-22.5 weeks). Other cranial biometric ratios also were calculated. RESULTS: The FTD was best predicted from the estimated gestational age (EGA) in the euploid population with the quadratic equation FTD = -0.0120 x EGA2 + 0.6917 x EGA - 5.2349 (R2 = .731) or from the biparietal diameter (BPD) with the linear equation FTD = 0.6837 x BPD + 0.5525 (R2 = .731). If an observed-to-expected ratio of 0.84 is used as a cutoff sign to screen for trisomy 21, a sensitivity of 16%, specificity of 97%, odds ratio of 6.03 (95% confidence interval, 1.81, 20.1), and relative risk of 5.98 are achieved. CONCLUSION: The frontal lobe is statistically significantly smaller in fetuses with trisomy 21. US measurement of the FTD may prove to be a useful adjunctive screening tool if used with other markers for Down syndrome.
Down Syndrome↗
Ultrasonographic diagnosis of trisomy 18: is it practical in the early second trimester?
The objective of this paper was to determine the rate of prenatal detection of ultrasonographic abnormalities in fetuses with trisomy 18 during the early second trimester. Our prenatal diagnosis database (encompassing January 1987 to June 1996) was searched for all patients referred for prenatal genetic evaluation between 14 and 22 weeks of gestation and who were found to have a fetus with a trisomy 18 karyotype. The sonographic reports and films were evaluated for the presence or absence of fetal anatomic abnormalities. Thirty-five fetuses were identified with a mean age of 17.3+/-2.0 (standard deviation) weeks. Thirty of the 35 (86%) had at least one detected abnormality. Most fetuses had more than one abnormality, with the mean number of abnormalities per fetus being three (range, 0 to 6). The most common abnormalities noted were persistent abnormal position of fetal fingers (89%); choroid plexus cysts (43%); abnormally shaped fetal head (strawberry or lemon) (43%); two-vessel umbilical cord (40%); cardiac defects (37%); intrauterine growth restriction (29%); omphalocele (20%); neural tube defects (9%); and cystic hygroma or lymphangiectasia (14%). Abnormalities of amniotic fluid volume (12%) and renal defects (9%) were seen less frequently. These data suggest that in the early second trimester, the time of most routine screening ultrasonographic examinations, most but not all fetuses with trisomy 18 have sonographically detectable anatomic abnormalities. The fetal hand appears to be abnormal in most early second trimester fetuses with trisomy 18, but the abnormality may be subtle and or unilateral.
Adolescent↗
Congenital masses of the lung: changes in cross-sectional area during gestation.
PURPOSE: We assessed the growth of congenital masses of the lung during gestation using computer-assisted planimetry. METHODS: The prenatal sonograms of 8 fetuses with congenital masses of the lung were reviewed. RESULTS: The cross-sectional area of the mass and chest were measured on the same transverse image using computer-assisted planimetry, and the percentage of the chest occupied by the mass was determined for each study. Four masses had pathologic features of type II congenital cystic adenomatoid malformation and intralobar sequestration (CCAM/ILS), 2 were type II CCAM, 1 was type I CCAM, and 1 was bronchial atresia with bronchiectasis. Four masses increased in cross-sectional area during gestation, 1 decreased, 2 were essentially unchanged, and 1 showed an initial increase in cross-sectional area followed by a decrease later in gestation. No consistent growth pattern was seen among masses with similar histologic characteristics. The percentage of the cross-sectional area of the chest occupied by the mass decreased in 7 fetuses and was virtually unchanged in 1 during gestation. All the fetuses survived to term; the infants had an uncomplicated postnatal course and underwent surgical resection of the mass during the first year of life. CONCLUSIONS: This study showed that in a fetus with a congenital mass of the lung and a favorable clinical outcome, growth of the chest exceeds any growth of the mass that may occur and masses with the same pathologic diagnosis have different patterns of growth in utero.
Bronchial Diseases↗
Disappearing fetal lung masses: importance of postnatal imaging studies.
BACKGROUND: The "disappearance" of congenital masses of the lung on prenatal sonograms has been described, but the importance of postnatal imaging studies in these children is unknown. OBJECTIVE: The objective of this work was to study the utility of radiographs and CT scans in asymptomatic infants with congenital masses of the lung that partially or completely resolve on prenatal sonograms performed late in gestation. MATERIALS AND METHODS: The prenatal sonograms, postnatal imaging studies, surgical findings, and pathologic diagnoses of seven children with an echogenic mass of the lung that improved or disappeared on prenatal sonograms were reviewed. RESULTS: All masses were type II congenital cystic adenomatoid malformation, with features of intralobar sequestration also being found in four. An unsuspected extralobar sequestration adjacent to a left lower lobe mass was found at surgery in one patient. All masses were hyperechoic compared with normal lung on sonograms prior to 32 weeks of gestation, with cysts being seen in four. On scans after 32 weeks, four of the masses had resolved completely and three showed subtle increased echogenicity compared with normal lung. Cysts completely resolved in two of four cases. Postnatal radiographs showed subtle abnormalities in four infants, a hyperlucent lobe in one, a soft tissue mass with adjacent hyperlucency in one, and normal findings in one. CT scans were abnormal in all cases, with air-filled cysts and soft tissue in six and a hyperinflated lobe in one. CONCLUSION: Children with "disappearing" fetal lung masses have persistent abnormalities after birth that are often subtle on radiographs but are well demonstrated with CT.
Cystic Adenomatoid Malformation of Lung, Congenita↗
Normal adult epididymis: evaluation with color Doppler US.
PURPOSE: To reevaluate blood flow patterns in the normal epididymis with color Doppler sonography. MATERIALS AND METHODS: Twenty-seven healthy volunteers (aged 19-68 years) with no history of scrotal disease, infection, or surgery (including vasectomy) underwent gray-scale imaging, color Doppler imaging, and pulsed Doppler spectral analysis of the head, body, and tail of each epididymis. All volunteers had negative results of urinalysis. RESULTS: In each of the 54 epididymides, blood flow was detected with pulsed Doppler and color Doppler imaging 100% of the time in the head, body, and tail. The mean resistive indexes for the right epididymal head, body, and tail were 0.55, 0.55, and 0.58, respectively. Similar values for the left side were 0.54, 0.55, and 0.55, respectively. None of these values were statistically significantly different. CONCLUSION: With current ultrasound imaging technology, epididymal flow was demonstrated not only in the head but also in the body and tail of the epididymides of all of our healthy volunteers. Thus, detection of flow in the epididymis at color Doppler imaging can be a normal finding and does not necessarily imply epididymitis.
Adult↗
Cavernous hemangiomas of the liver: enlargement over time.
OBJECTIVE: It has been reported that cavernous hemangiomas of the liver either do not enlarge over time, or, of the very few lesions that have shown an increase in diameter on follow-up imaging studies, the increase has been minimal. The objective of this paper is to report growth of four cavernous hemangiomas that were shown to have doubled to tripled in diameter on follow-up imaging studies done between 34 months and 10.5 years after the initial diagnosis. CONCLUSION: This report indicates that hepatic hemangiomas can grow significantly in diameter, although such growth is unusual. Despite the growth of the lesion, however, if the imaging features are characteristic of hemangioma an imaging diagnosis can still be made confidently.
Adult↗
Prenatal evaluation of mesenchymal hamartoma of the liver: gray scale and power Doppler sonographic imaging.
Explore the source record for details and available documents.
Adult↗
CT angiography of the visceral vessels.
CT angiography (CTA) is a promising new technique for vascular imaging. This review focuses first on the technique necessary for successful scanning of the visceral vessels. As in many new modalities, there are different protocols for scanning and rendering of images. The relative strengths and weaknesses of these different approaches are discussed. A discussion of the applications of CTA to depict normal and abnormal anatomy of the visceral vessels follows. These applications include celiac stenosis, splenic artery aneurysms, evaluation for hepatic arterial anatomy before liver transplantation, visceral arterial anatomy in pancreaticoduodenal surgery, the superior mesenteric artery in intestinal ischemia, vascular encasement in patients with pancreatic neoplasms, and, finally, the hepatic vessels before hepatic tumor resection.
Angiography↗
MR angiography of the portal venous system.
MR angiography (MRA) has become an increasingly important and practical clinical tool for the noninvasive assessment of abdominal vessels. Both two-dimensional time-of-flight and phase contrast techniques allow accurate evaluation of the portal venous system. This article reviews these two MRA techniques and discusses their impact on the diagnosis of vascular abnormalities of the portal venous system.
Humans↗